Trials / Unknown
UnknownNCT05316077
Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-up
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Guerbet · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted within the frame of the Post-Market Surveillance (PMS) activities, as described in the Post Market Clinical Follow-up (PMCF) plan of Vectorio®. This study aims at collecting clinical data, to confirm the General Safety and Performance Requirements of Vectorio® which is a Lipiodol Resistant Mixing \& Injection System for cTACE.
Conditions
Timeline
- Start date
- 2022-08-30
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
- First posted
- 2022-04-07
- Last updated
- 2022-09-15
Locations
3 sites across 3 countries: Austria, France, Switzerland
Source: ClinicalTrials.gov record NCT05316077. Inclusion in this directory is not an endorsement.